Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-30

Clinical Trial Update: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of Tecemotide (L-BLP25) in non-small cell lung cancer terminated after concurrent chemoradiotherapy; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tecemotide (L-BLP25) (tecemotide)

Snippet

Sponsor: EMD Serono | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2017-03-30